Pharmaceutical Clinical Trial Data False Claims: What Was Suppressed or Misstated?

Pharmaceutical clinical trial data false claims arise when a company knowingly uses misleading safety or efficacy information to cause government programs to pay for prescriptions. The study inside the company may tell a different story from the article, sales presentation or coverage submission outside it. If you worked on the analysis, reviewed the safety findings or approved the medical copy, you may know where that story changed.

The useful comparison follows the result from the study to the message and then to the payment. A finding can disappear from publication, shrink when combined with other data, or become a claim of superiority the study never tested. The people who recognize those changes often work far from the pharmacy that submits the bill.

Are Pharmaceutical Companies Liable for False Claims?

A pharmaceutical company is liable under the False Claims Act for knowingly causing false claims that a pharmacy or physician submits.

That connection gives clinical and medical-writing work financial consequences. A claim about benefit in another patient group can expand the audience for that product. The question for a whistleblower case is how the company used that claim to generate prescriptions that Medicare, Medicaid or another government healthcare program paid.

For an insider, that means connecting what the company knew with what it told the people making treatment and payment decisions. A published article, a sales aid and a presentation to a Medicaid formulary committee can each carry the same unsupported message to a different audience. The cases below show those connections in concrete terms.

GSK and the Avandia Civil Settlement

GlaxoSmithKline’s Avandia civil settlement concerned alleged misrepresentations about the drug. The Justice Department’s July 2012 resolution included $657 million to settle the alleged misstatements about Avandia.

Abbott and the Depakote Safety and Efficacy Claims

Abbott’s Depakote civil settlement addressed allegations that misleading statements about safety, efficacy, dosing and cost-effectiveness helped sell the drug for unapproved uses. The government’s allegations reached treatment of behavioral disturbances in dementia patients, schizophrenia and other conditions.

In its May 2012 announcement, the Justice Department said Abbott agreed to $800 million in civil settlements with the federal government and participating states. The alleged marketing and payment practices caused false claims to programs including Medicare and Medicaid. Some promoted uses fell outside the uses those programs covered.

The nursing-home pitch also attached a business advantage to the clinical message. The government alleged that Abbott claimed Depakote could help nursing homes avoid administrative burdens and costs associated with restrictions on antipsychotic drugs. The audience heard an argument about easier operations alongside the claims about treating residents.

The government’s account also included alleged payments to health care professionals and long-term care pharmacy providers to induce prescribing and promotion.

Janssen and Risperdal Risk Presentation

Janssen allegedly made unfavorable Risperdal findings look less troubling by combining studies, withholding findings and commissioning a new analysis. The Justice Department’s account of its civil complaint describes what happened to the data at each stage.

The complaint described a study showing a significant risk of strokes and other adverse events in elderly dementia patients. It alleged that Janssen combined those results with other studies to make the overall risk appear lower. According to the complaint, a second study confirmed increased safety risks. Its findings remained unpublished a year after Johnson & Johnson received them, prompting a physician involved in the work to question the delay.

The diabetes allegations involved a different change. According to the complaint, Janssen received initial study results indicating that Risperdal posed the same diabetes risk as other antipsychotics. The company allegedly hired outside consultants to reanalyze the results and ultimately published articles describing a lower risk.

The contrast is specific enough for a statistician or medical writer to recognize. The initial analysis, the decision to combine studies, the instructions to consultants and the article’s final conclusion tell different parts of the story. The government also alleged that the companies knew about serious risks while downplaying them in promotion.

The complaint connected this conduct to false claims through promotion for uses federal health care programs did not cover, misleading safety and efficacy statements, and payments to prescribers. It alleged that Janssen targeted elderly nursing-home residents, children and people with mental disabilities. The alleged pitch downplayed risks to patients while taxpayers paid for the prescriptions. The alleged distortion began much earlier, in the handling of the evidence used to sell the drug.

What Evidence Is Needed to Prove Fraud?

Evidence in a clinical-data false-claims case connects the underlying findings, the message used to promote or secure coverage for the drug, the company’s knowledge and the resulting government claims. We examine those connections with the people who know how the study and the commercial decisions unfolded.

The same comparison applies to scientific claims about a different patient population or treatment outcome. What did the study set out to measure? What did the final sales message say it proved? What did the people reviewing that message know? A medical writer may recognize the changed conclusion. A sales employee may recognize the instruction to keep using it. Their knowledge can connect decisions that otherwise sit in separate departments.

Coverage records and claims supply the next connection. A formulary presentation shows what the company told the payer. A drug-reference listing can show how a scientific assertion became support for reimbursement. Those records help us follow the disputed finding beyond the journal page.

Why Access to the Full Findings Matters

Publication and access to study data shape what clinicians can learn about a drug. The literature review Corporate Crime in the Pharmaceutical Industry Is Common, Serious and Repetitive, from the Nordic Cochrane Centre in 2012, identified recurring misrepresentation of results and concealment of harm data in the cases it examined.

Its discussion of research disclosure examines the gap between information held by companies and regulators and information available publicly. The review argues for disclosure by both manufacturers and drug agencies. Its warning in 2012 was plain:

The Janssen allegations show why that gap matters to a prescriber: a published article can present a different risk picture from the findings the company holds.

Shire and a Comparison the Study Did Not Make

Shire’s Adderall XR allegations show how a study can acquire a stronger claim as it moves into promotion. A whistleblower’s complaint alleged that Shire marketed the drug as superior to competing products in normalizing children with attention deficit hyperactivity disorder.

The complaint challenged what the study could actually support:

The same passage alleged that the comparison between drugs came from an analysis conducted after the fact. The sales claim promised a comparative benefit. The complaint alleged that the study had not been designed to measure it.

The September 2014 civil settlement announcement described a $56.5 million settlement covering marketing allegations involving several Shire drugs. Among them were overstated Adderall XR efficacy claims and allegedly misleading statements about Vyvanse’s efficacy and potential for abuse to physicians and state Medicaid formulary committees.

Those committees put the payer inside the scientific-message story. The allegedly unsupported presentation reached people making decisions about access to the drug as well as the clinicians prescribing it.

Abbott’s TriCor Complaint and the Missing Risk Message

A separate whistleblower complaint about Abbott’s TriCor alleged that sales training omitted risks that appeared in the product insert. The allegations concerned promotion of TriCor in combination with statins and the studies representatives used with doctors.

The complaint alleged that representatives received one combination-therapy study to leave with physicians, while another study addressing dangers did not reach them:

The complaint also alleged that Abbott coached representatives to downplay the FIELD study’s lack of positive coronary heart disease mortality results. It described instructions to leave off-label discussions out of call notes.

For someone reviewing medical communications, these allegations point to the selection and handling of the message. A company can distribute a paper and still allegedly train its staff to minimize the finding that matters. Training materials, the product insert, the papers provided to representatives and instructions about documenting their conversations offer different views of the same promotion.

Amgen and the Route From an Article to Reimbursement

An Amgen whistleblower complaint alleged a direct path from misleading science to government coverage. It accused Amgen and Thomson of using ghostwritten articles and allegedly tainted studies to support Aranesp for anemia of cancer.

The complaint described drug-reference listings as the connection. It alleged that the studies supported listings in Thomson-owned drug compendia, and that the government then used those listings as the basis for reimbursement decisions. It also alleged that Amgen concealed its central role in organizing the studies and determining their findings.

The disputed science allegedly moved into a reference used for coverage, then into reimbursement. Someone working on the manuscript or the compendium submission may understand a decision that is invisible on the eventual claim.

Research Payments and Research Results

Research payments can create another connection to prescribing. In a separate civil case, the government alleged that Amgen changed its Xgeva data-purchase program so that payments went only to doctors who prescribed the drug. The original design had called for collecting information about treatment whether or not Xgeva was prescribed.

That allegation concerns what the payment bought. The Aranesp complaint concerns what the scientific message said and how it supported reimbursement. An insider may see both a study’s commercial arrangements and its results. We examine each connection to the prescriptions it helped generate.

What Proof Do You Need as a Whistleblower?

Your starting point may be firsthand knowledge of a particular study, safety finding, publication decision or payer presentation. We connect that knowledge to the company’s records and the government-payment question with you.

A statistician may know why an analysis changed. A medical reviewer may know which warning disappeared from a presentation. A medical science liaison may know what a Medicaid committee was told. The value lies in the connection between the information inside the company and the decision made outside it.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

When You Know What the Study Really Said

If you know why a finding disappeared or a safety message changed, speak with our whistleblower experts about the study and the decisions behind it. We work beside you to build your strongest pharmaceutical whistleblower case around the science, the company’s knowledge and the government payments, and bring in pharmaceutical whistleblower lawyers who understand clinical evidence. Your knowledge of the original findings gives that work its starting point, and we stay with you through the case.